What happens when you take valproate with carnitine?
Valproate (also sold as valproic acid, divalproex, sodium valproate, and under brand names like Depakote and Depakene) is one of the most widely prescribed broad-spectrum anticonvulsants and a mainstay treatment for epilepsy, bipolar disorder, and migraine prevention. Although effective, the drug has a well-documented metabolic side effect: it depletes the body's stores of carnitine, a small molecule essential for shuttling long-chain fatty acids into the mitochondria for energy production.
The depletion happens through several routes. Valproate is itself partly metabolized through mitochondrial beta-oxidation, the same pathway carnitine serves. To enter the mitochondria, valproate forms a conjugate with carnitine called valproyl-carnitine, which is then excreted in the urine, carrying carnitine with it. On top of that, valproate impairs renal tubular reabsorption of free carnitine, meaning the kidneys allow more of it to slip away than they normally would. Long-term therapy can leave patients with measurably lower plasma and tissue carnitine.
When carnitine runs short, fatty-acid oxidation slows. That has downstream effects on the urea cycle, the biochemical pathway the liver uses to dispose of ammonia. Specifically, less acetyl-CoA is generated, which lowers production of N-acetylglutamate — an allosteric activator the urea cycle's first enzyme (carbamoyl phosphate synthetase 1) requires to function. The result can be a build-up of ammonia in the blood, a state called hyperammonemia, that may present as drowsiness, confusion, vomiting, tremor, or in severe cases encephalopathy.
Why is this important?
Valproate-associated hyperammonemia is not rare. Studies have detected elevated ammonia in a substantial minority of patients on chronic valproate, and a smaller fraction develop overt symptoms of valproate-induced hyperammonemic encephalopathy (VHE). Children, patients on multiple anticonvulsants, those with intellectual disability, individuals with a previously unrecognized urea cycle disorder, and people on high-dose or long-term therapy face the greatest risk.
The consequences range from quiet, sub-symptomatic cognitive slowing all the way to coma. Acute valproate overdose can trigger life-threatening hyperammonemia. Even in routine outpatient care, low carnitine status has been linked to fatigue, muscle weakness, hair loss, and contribution to valproate-related hepatotoxicity.
Carnitine supplementation has been studied as both a preventive measure and a treatment. A widely cited 2017 case report in the Journal of International Medical Research described a woman whose chronic valproate-induced hyperammonemia normalized after a month of oral L-carnitine 1 gram per day, with no need to discontinue her anticonvulsant. Intravenous levocarnitine is recommended by the Pediatric Neurology Society for symptomatic hyperammonemia or hepatotoxicity, and it is widely used in critical-care protocols for valproate overdose. Oral L-carnitine is used for chronic prophylaxis in higher-risk patients.
What should you do?
This is a medication issue, so the conversation belongs with your neurologist or psychiatrist rather than something you handle alone. If you are on valproate and notice unusual fatigue, brain fog, drowsiness, or worsening tremor, ask your prescriber to check a fasting ammonia level. A ratio of free to total carnitine in serum can also help clarify whether you are depleted.
For patients on long-term valproate — particularly children, those on polytherapy, and anyone with a known metabolic disorder — many epilepsy clinicians proactively recommend oral L-carnitine in the range of 50 to 100 mg/kg/day (capped at 2 to 3 grams daily for adults), divided across the day. Lower maintenance doses (around 1 to 2 grams per day) are sometimes used in adults without overt deficiency. Do not start carnitine on your own at high doses; doses above roughly 3 grams a day can cause a fishy body odor (trimethylaminuria), nausea, and diarrhea.
Track your symptoms in Pilora and bring objective data — ammonia, free and total carnitine, liver enzymes — to your next visit. Do not stop or change valproate doses without medical guidance, since uncontrolled seizures or mood episodes pose a far greater risk than the carnitine depletion itself.
Which specific products are affected?
The interaction applies to all valproate-containing prescription drugs, including Depakote, Depakote ER, Depakote Sprinkles, Depakene, Depacon, divalproex sodium, sodium valproate, and valproic acid. Both immediate-release and extended-release formulations cause carnitine depletion, although extended-release products may produce somewhat smaller swings in plasma ammonia.
On the supplement side, L-carnitine is available as L-carnitine tartrate, acetyl-L-carnitine (ALCAR), propionyl-L-carnitine, and as the prescription form levocarnitine (Carnitor). For valproate-related depletion the preferred forms are L-carnitine tartrate or levocarnitine; acetyl-L-carnitine crosses into the brain more readily and is sometimes preferred when cognitive symptoms predominate, but it has been less extensively studied for this specific purpose. Avoid D-carnitine or DL-carnitine mixtures — only the L-isomer is biologically active.
The bottom line
Valproate steadily depletes carnitine through urinary loss as valproyl-carnitine and reduced renal reabsorption, and the resulting carnitine shortfall can impair the urea cycle and contribute to hyperammonemia, hepatic stress, and fatigue. If you are on valproate long-term or at high doses, talk with your prescriber about checking ammonia and carnitine levels and consider supervised L-carnitine supplementation — it is one of the few clearly evidence-based supplement additions to anticonvulsant therapy.